BR122018074426B8 - método de geração de células t com atividade reguladora - Google Patents

método de geração de células t com atividade reguladora

Info

Publication number
BR122018074426B8
BR122018074426B8 BR122018074426A BR122018074426A BR122018074426B8 BR 122018074426 B8 BR122018074426 B8 BR 122018074426B8 BR 122018074426 A BR122018074426 A BR 122018074426A BR 122018074426 A BR122018074426 A BR 122018074426A BR 122018074426 B8 BR122018074426 B8 BR 122018074426B8
Authority
BR
Brazil
Prior art keywords
apoptotic
generation method
cell generation
cell
regulatory activity
Prior art date
Application number
BR122018074426A
Other languages
English (en)
Other versions
BR122018074426B1 (pt
Inventor
Krutsick Amy
Peritt David
Campbell Kim
Original Assignee
Therakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therakos Inc filed Critical Therakos Inc
Publication of BR122018074426B1 publication Critical patent/BR122018074426B1/pt
Publication of BR122018074426B8 publication Critical patent/BR122018074426B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

muitos tipos de célula no corpo podem remover restos apoptóticos e celulares de tecidos; no entanto, o fagócito profissional, ou célula apresentando antígeno ("apc"), tem uma alta capacidade para fazer isso. o reconhecimento de células apoptóticas ("acs") acontece através de uma série de receptores de padrão molecular associados a ac, evolucionariamente conservados, ("acamprs") em apcs que reconhecem e se ligam a padrões moleculares associados à célula apoptótica correspondentes ("acamps"). esses receptores reconhecem ligantes tais como fosfotidil serina e lipídeos oxidados encontrados em células apoptóticas. savill e outros (200); e gregory e outros (2004).
BR122018074426A 2005-11-02 2006-11-02 método de geração de células t com atividade reguladora BR122018074426B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73284705P 2005-11-02 2005-11-02
PCT/US2006/042581 WO2007055992A2 (en) 2005-11-02 2006-11-02 The use of apoptotic cells ex vivo to generate regulatory t cells
BRPI0618139-2A BRPI0618139A2 (pt) 2005-11-02 2006-11-02 método de geração de células t com atividade reguladora, composição compreendendo uma população das referidas células e uso das mesmas

Publications (2)

Publication Number Publication Date
BR122018074426B1 BR122018074426B1 (pt) 2019-12-10
BR122018074426B8 true BR122018074426B8 (pt) 2021-07-27

Family

ID=38023783

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018074426A BR122018074426B8 (pt) 2005-11-02 2006-11-02 método de geração de células t com atividade reguladora
BRPI0618139-2A BRPI0618139A2 (pt) 2005-11-02 2006-11-02 método de geração de células t com atividade reguladora, composição compreendendo uma população das referidas células e uso das mesmas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0618139-2A BRPI0618139A2 (pt) 2005-11-02 2006-11-02 método de geração de células t com atividade reguladora, composição compreendendo uma população das referidas células e uso das mesmas

Country Status (8)

Country Link
US (5) US9169461B2 (pt)
EP (2) EP1951036A4 (pt)
JP (1) JP2009514530A (pt)
CN (1) CN101351118B (pt)
BR (2) BR122018074426B8 (pt)
CA (1) CA2628341A1 (pt)
ES (1) ES2633102T3 (pt)
WO (1) WO2007055992A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169461B2 (en) * 2005-11-02 2015-10-27 Therakos, Inc. Use of apoptotic cells ex vivo to generate regulatory T cells
US10069924B2 (en) 2007-07-25 2018-09-04 Oath Inc. Application programming interfaces for communication systems
WO2009132283A2 (en) * 2008-04-24 2009-10-29 University Of Miami Method for treating autoimmune disorders
US20130252227A1 (en) * 2012-03-20 2013-09-26 Fenwal, Inc. Apparatus and Method for Providing Cryopreserved ECP-Treated Mononuclear Cells
EP2929015B1 (en) 2012-12-06 2019-09-18 Enlivex Therapeutics Ltd. Therapeutic apoptotic cell preparations, method for producing same and uses thereof
CA3116336A1 (en) * 2018-10-19 2020-04-23 Regents Of The University Of Minnesota Transplant tolerance induction with carbodiimide treated tolerizing vaccine
CN110367242A (zh) * 2019-08-02 2019-10-25 陕西佰傲干细胞再生医学有限公司 凋亡小体保存液及凋亡小体的保存方法
ES2927913B2 (es) * 2021-05-07 2023-07-27 Univ Murcia Composición que comprende una combinación de las furanocumarinas psoraleno y angelicina y su uso en terapia
CN113444684B (zh) * 2021-06-08 2022-06-14 浙江大学 修复子宫内膜并提高生育力的干细胞凋亡小体的制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562283A (en) 1896-06-16 Keyed cithern
US4398906A (en) 1979-12-11 1983-08-16 Frederic A. Bourke, Jr. Method for externally treating the blood
US4321919A (en) * 1979-12-11 1982-03-30 Leukocyte Research, Inc. Method and system for externally treating human blood
US4428744A (en) 1979-12-11 1984-01-31 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4464166A (en) * 1981-06-12 1984-08-07 Frederic A. Bourke, Jr. Method for externally treating the blood
US4683889A (en) 1983-03-29 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US5512332A (en) 1985-10-04 1996-04-30 Immunivest Corporation Process of making resuspendable coated magnetic particles
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US5104526A (en) 1987-01-30 1992-04-14 Baxter International Inc. Centrifugation system having an interface detection system
US5108933A (en) 1988-09-16 1992-04-28 Immunicon Corporation Manipulation of colloids for facilitating magnetic separations
JP2710967B2 (ja) * 1988-11-22 1998-02-10 株式会社日立製作所 集積回路装置の製造方法
US5242974A (en) * 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5698271A (en) 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5622831A (en) * 1990-09-26 1997-04-22 Immunivest Corporation Methods and devices for manipulation of magnetically collected material
US6013532A (en) * 1990-09-26 2000-01-11 Immunivest Corporation Methods for magnetic immobilization and manipulation of cells
US5541072A (en) 1994-04-18 1996-07-30 Immunivest Corporation Method for magnetic separation featuring magnetic particles in a multi-phase system
US5646001A (en) * 1991-03-25 1997-07-08 Immunivest Corporation Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof
US5466574A (en) 1991-03-25 1995-11-14 Immunivest Corporation Apparatus and methods for magnetic separation featuring external magnetic means
US5186827A (en) 1991-03-25 1993-02-16 Immunicon Corporation Apparatus for magnetic separation featuring external magnetic means
US5795470A (en) * 1991-03-25 1998-08-18 Immunivest Corporation Magnetic separation apparatus
US5242984A (en) 1991-07-29 1993-09-07 Shell Oil Company Sequentially polymerized styrene-isoprene-styrene block copolymer adhesive composition
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5730883A (en) * 1991-12-23 1998-03-24 Baxter International Inc. Blood processing systems and methods using apparent hematocrit as a process control parameter
WO1994019031A1 (en) 1993-02-18 1994-09-01 Baxter International Inc. Apheresis system incorporating alternative site for anticoagulant addition
SE501070C2 (sv) * 1993-03-26 1994-11-07 Ericsson Telefon Ab L M System och förfarande för dispersionskompensering i fiberoptiska höghastighetssystem
US5399719A (en) * 1993-06-28 1995-03-21 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
US5741714A (en) 1995-07-18 1998-04-21 Immunivest Corporation Detection of bound analyte by magnetic partitioning and masking
US6251284B1 (en) * 1995-08-09 2001-06-26 Baxter International Inc. Systems and methods which obtain a uniform targeted volume of concentrated red blood cells in diverse donor populations
US5660990A (en) 1995-08-18 1997-08-26 Immunivest Corporation Surface immobilization of magnetically collected materials
WO1997036581A1 (en) 1996-03-29 1997-10-09 Therakos, Inc. Photopheresis treatment of leukocytes
DE69734450T2 (de) 1996-03-29 2006-08-10 Therakos, Inc. Photopherese-behandlung von hcv-infektionen
US6473623B1 (en) * 1996-04-18 2002-10-29 At&T Wireless Services, Inc. Method for self-calibration of a wireless communication system
US6136182A (en) 1996-06-07 2000-10-24 Immunivest Corporation Magnetic devices and sample chambers for examination and manipulation of cells
WO1997046882A1 (en) * 1996-06-07 1997-12-11 Immunivest Corporation Magnetic separation employing external and internal gradients
US6228624B1 (en) * 1996-08-02 2001-05-08 Immunivest Corporation Method to select and transfect cell subpopulations
GB9621231D0 (en) * 1996-10-11 1996-11-27 Exxon Chemical Patents Inc Low sulfer fuels with lubricity additive
US5951509A (en) 1996-11-22 1999-09-14 Therakos, Inc. Blood product irradiation device incorporating agitation
US6027441A (en) 1997-07-01 2000-02-22 Baxter International Inc. Systems and methods providing a liquid-primed, single flow access chamber
IL133913A0 (en) 1997-07-10 2001-04-30 Therakos Inc Treatment of inflammatory disorders of the bowel and urinary bladder
JP3987900B2 (ja) * 1997-11-26 2007-10-10 アークレイ株式会社 糖化タンパク質の測定方法
BR9907852A (pt) 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
US6361749B1 (en) * 1998-08-18 2002-03-26 Immunivest Corporation Apparatus and methods for magnetic separation
DE60023677T2 (de) 1999-04-16 2006-08-24 Becton Dickinson And Co. Stiftförmiger injektor mit merkmalen zur automatischen substanzkombination
US20050084966A1 (en) 1999-04-20 2005-04-21 Edelson Richard L. Methods for inducing the differentiation of blood monocytes into functional dendritic cells
US6219584B1 (en) 1999-07-09 2001-04-17 Therakos, Inc. Method and system for determining an effective amount of light energy to delivery to fluids having targets for the light energy
US6284142B1 (en) 1999-09-03 2001-09-04 Baxter International Inc. Sensing systems and methods for differentiating between different cellular blood species during extracorporeal blood separation or processing
US6315707B1 (en) 1999-09-03 2001-11-13 Baxter International Inc. Systems and methods for seperating blood in a rotating field
US6793643B1 (en) 2000-04-21 2004-09-21 Therakos, Inc. Low extracorporeal volume treatment system
US7727523B2 (en) * 2001-08-13 2010-06-01 Yale University Method for suppressing immune system response to transplanted tissue or cells
CN1310652C (zh) * 2001-11-29 2007-04-18 特拉科斯有限公司 用体外光提取法和/或凋亡细胞对被试者进行预治疗的方法
WO2004090095A2 (en) 2003-04-01 2004-10-21 University Of Southern California Generation of human regulatory t cells by bacterial toxins for the treatment of inflammatory disorders
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
US9169461B2 (en) * 2005-11-02 2015-10-27 Therakos, Inc. Use of apoptotic cells ex vivo to generate regulatory T cells
WO2015187940A1 (en) 2014-06-05 2015-12-10 Wake Forest University Health Sciences Methods and compounds for phototherapy with chalcogenorhodamine photosensitizers

Also Published As

Publication number Publication date
JP2009514530A (ja) 2009-04-09
WO2007055992A2 (en) 2007-05-18
WO2007055992A3 (en) 2007-10-04
EP1951036A4 (en) 2009-05-27
US20160046909A1 (en) 2016-02-18
US20190055516A1 (en) 2019-02-21
EP2443922B1 (en) 2017-05-03
US10138464B2 (en) 2018-11-27
EP2443922A1 (en) 2012-04-25
EP1951036A2 (en) 2008-08-06
CN101351118B (zh) 2015-05-27
US20070098686A1 (en) 2007-05-03
BR122018074426B1 (pt) 2019-12-10
US9169461B2 (en) 2015-10-27
US20210388318A1 (en) 2021-12-16
CA2628341A1 (en) 2007-05-18
BRPI0618139A2 (pt) 2011-08-16
US11124767B2 (en) 2021-09-21
CN101351118A (zh) 2009-01-21
ES2633102T3 (es) 2017-09-19
US20080267934A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
BR122018074426B8 (pt) método de geração de células t com atividade reguladora
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
BRPI0516857A (pt) dispositivos biomédicos que contêm copolìmeros de bloco anfifìlico
ATE555380T1 (de) Verfahren zur änderung des schicksals von zellen
ATE457469T1 (de) Polymerisierbare tenside und deren verwendung als comonomerbildende vorrichtung
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
HK1086480A1 (en) Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
ES2530780T3 (es) Composiciones y métodos para el tratamiento de trastornos oculares
DE602004021585D1 (de) 5,7-DIAMINOPYRAZOLOi4,3-D PYRIMIDINE ZUR VERWENDUNG IN DER BEHANDLUNG VON BLUTHOCHDRUCK
MX2010007936A (es) Anticuerpo anti-nr-10 y su uso.
TN2012000450A1 (en) Biomarkers for mdm2 inhibitors for use in treating disease
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
BR112014032152A2 (pt) partículas abrasivas tendo formatos particulares e métodos para formar tais partículas
AR043331A1 (es) Composiciones para el cuidado personal o domestico que comprende nuevas gomas, ceras y aceites hidrofobos a base de silicona
CY1112259T1 (el) Συνθεσεις οι οποιες περιλαμβανουν ορνιθινη και φαινυλοξικο ή φαινυλοβουτυρικο για αντιμετωπιση ηπατικης εγκεφαλοπαθειας
ECSP066364A (es) Moléculas de lubricina recombinantes y usos de las mismas
DE602005017893D1 (de) Drehverfahren für silikonhydrogel-linsen
ATE441385T1 (de) Implantat zur verwendung als ersatz eines orbitabodens
DE602004029034D1 (de) Replikin-peptide und anwendungen
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
DE60043775D1 (de) Verfahren zum identifizieren von präneoplastischen und neoplastischen stadien in säugern
ATE411279T1 (de) Arylsulfonamidobenzylverbindungen
UY28345A1 (es) Compuestos novedosos
ATE458807T1 (de) Oberfläche für zellkultur

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO